nature.com search

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Search
My Account Login

nature
search

advanced

where the list of authors contains where the title contains

Refine your results by…

volume

start page / article no.

Filters

Filter By:

Article type

Check one or more article types to show results from those article types only.

Research (5)

Journal

Check one or more journals to show results from those journals only.

Leukemia (7)

Choose more journals

Subject Check one or more subjects to show results from those subjects only.

Acute myeloid leukaemia (2)
Myelodysplastic syndrome (2)
Anaemia (1)
Cancer metabolism (1)
Cancer microenvironment (1)

Date

Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
In the last year
Last 2 years
Last 5 years

Custom date range

Sort by Relevance

Choose a way to sort results.

Relevance
Date — most recent
Date — oldest first

Loading Filters

Showing 1–7 of 7 results

Loading Filters

3 October 2017
Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling
- G Kerdivel
- , V Chesnais
- , E Becht
- , A Toma
- , N Cagnard
- , F Dumont
- , A Rousseau
- , P Fenaux
- , S Chevret
- , N Chapuis
- , V Boeva
- , W H Fridman
- , M Fontenay
- & O Kosmider
Leukemia 32 , 558–562

Rights & permissionsfor article Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling . Opens in a new window.
Research | 14 June 2013
Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes
- S Mathis
- , N Chapuis
- , C Debord
- , A Rouquette
- , I Radford-Weiss
- , S Park
- , F Dreyfus
- , C Lacombe
- , M C Béné
- , O Kosmider
- , M Fontenay
- & V Bardet
Leukemia 27 , 1981–1987

Rights & permissionsfor article Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes . Opens in a new window.
Research | 10 March 2017
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells
- L Poulain
- , P Sujobert
- , F Zylbersztejn
- , S Barreau
- , L Stuani
- , M Lambert
- , T L Palama
- , V Chesnais
- , R Birsen
- , F Vergez
- , T Farge
- , C Chenevier-Gobeaux
- , M Fraisse
- , F Bouillaud
- , C Debeissat
- , O Herault
- , C Récher
- , C Lacombe
- , M Fontenay
- , P Mayeux
- , T T Maciel
- , J-C Portais
- , J-E Sarry
- , J Tamburini
- , D Bouscary
- & N Chapuis
Leukemia 31 , 2326–2335

Rights & permissionsfor article High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells . Opens in a new window.
Research | 16 January 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse
- S Park
- , N Chapuis
- , F Saint Marcoux
- , C Recher
- , T Prebet
- , P Chevallier
- , J-Y Cahn
- , T Leguay
- , P Bories
- , F Witz
- , T Lamy
- , P Mayeux
- , C Lacombe
- , C Demur
- , J Tamburini
- , A Merlat
- , R Delepine
- , N Vey
- , F Dreyfus
- , M C Béné
- , N Ifrah
- & D Bouscary
Leukemia 27 , 1479–1486

Rights & permissionsfor article A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse . Opens in a new window.
Research | 12 June 2008
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
- S Park
- , N Chapuis
- , V Bardet
- , J Tamburini
- , N Gallay
- , L Willems
- , Z A Knight
- , K M Shokat
- , N Azar
- , F Viguié
- , N Ifrah
- , F Dreyfus
- , P Mayeux
- , C Lacombe
- & D Bouscary
Leukemia 22 , 1698–1706

Rights & permissionsfor article PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML . Opens in a new window.
12 August 2010
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
- N Chapuis
- , J Tamburini
- , A S Green
- , L Willems
- , V Bardet
- , S Park
- , C Lacombe
- , P Mayeux
- & D Bouscary
Leukemia 24 , 1686–1699

Rights & permissionsfor article Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies . Opens in a new window.
Research | 6 December 2011
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
- L Willems
- , N Chapuis
- , A Puissant
- , T T Maciel
- , A S Green
- , N Jacque
- , C Vignon
- , S Park
- , S Guichard
- , O Herault
- , A Fricot
- , O Hermine
- , I C Moura
- , P Auberger
- , N Ifrah
- , F Dreyfus
- , D Bonnet
- , C Lacombe
- , P Mayeux
- , D Bouscary
- & J Tamburini
Leukemia 26 , 1195–1202

Rights & permissionsfor article The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia . Opens in a new window.

Search

Article Search

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

nature.com sitemap

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
Nano
Protocol Exchange
Nature Index

Publish with us

Guide to Authors
Guide to Referees
Editorial policies
Open access
Reprints & permissions

Researcher services

Research data
Language editing
Scientific editing
Nature Masterclasses
Nature Research Academies

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Career development

Nature Careers
Nature Conferences
Nature events

Regional websites

Nature China
Nature India
Nature Japan
Nature Korea
Nature Middle East

Legal & Privacy

Privacy Policy
Use of cookies
Manage cookies/Do not sell my data
Legal notice
Accessibility statement
Terms & Conditions
California Privacy Statement

Refine your results by…

Filters ​

Filter By:

Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling

Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

Search

Quick links

Filters